OPDIVO + YERVOY |
---|
Dosing schedules
Find dosing information to get patients with unresectable or metastatic hepatocellular carcinoma started on therapy
Unresectable or Metastatic HCC1
1L Unresectable or Metastatic HCC OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC).
2L Unresectable or Metastatic HCC OPDIVO, in combination with YERVOY, is indicated for the treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
DOSING & SCHEDULE | DURATION |
---|---|
Induction phase*† | |
1 mg/kg of OPDIVO IV infusion over 30 minutes followed on the same day by 3 mg/kg of YERVOY IV infusion over 30 minutes | q3w for a maximum of 4 doses of combination therapy |
Maintenance phase | |
240 mg of OPDIVO IV infusion† over 30 minutes q2w OR 480 mg of OPDIVO IV infusion† over 30 minutes q4w‡ |
Until disease progression or unacceptable toxicity, or up to 2 years |
After completing 4 doses of the combination in the induction phase, administer OPDIVO as a single agent.
No premedications are required.
*When OPDIVO is administered in combination with YERVOY, if OPDIVO is withheld or discontinued, YERVOY should also be withheld or discontinued.1
†Interrupt or slow the rate of infusion in patients with mild or moderate infusion-related reactions. Discontinue OPDIVO or OPDIVO + YERVOY in patients with severe or life-threatening infusion-related reactions.1
‡Based on exploratory dose–exposure–response relationships for efficacy and safety, OPDIVO 240 mg q2w and 480 mg q4w are predicted to be similar.2
Review the U.S. Full Prescribing Information for OPDIVO and YERVOY.
Treatment Modifications
See recommended dosing modifications for immune-mediated adverse reactions.
Preparation and Administration
Find instructions for preparation, administration, infusion, and storage.
OPDIVO Dosing Guide
A guide to dosing across all indications.
References:
- OPDIVO [package insert]. Princeton, NJ: Bristol-Myers Squibb Company.
- Long GV, Tykodi SS, Schneider JG, et al. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer. Ann Oncol. 2018;29(11):2208-2213.